Abstract: The present invention pertains to the use of conjugated fumonisin (FUM) in a method to protect an animal against FUM induced mycotoxicosis, in particular to protect against a decrease in average daily weight gain, intestinal damage, liver damage and kidney damage as a result of the ingestion of FUM.

Abstract: The present invention pertains to the use of conjugated T-2 toxin (T2) in a method to protect an animal against T2 induced mycotoxicosis, in particular to protect against a decrease in average daily weight gain, intestinal damage, skin damage and snout damage, thus one or more of these signs of mycotoxicosis induced by T2 as a result of the ingestion of T2.

Abstract: The present invention pertains to the use of conjugated zearalenone (ZEA) in a method to protect an animal against ZEA induced mycotoxicosis, in particular to protect against decreased weight gain, kidney damage, liver damage and damage to a reproductive organ.

Abstract: The present invention pertains to the use of conjugated aflatoxin (AFB) in a method to protect an animal against AFB induced mycotoxicosis, in particular to protect against a decrease in average daily weight gain, immune suppression, icterus, hemorrhagic enteritis as a result of the ingestion of AFB.

Abstract: The present invention pertains to a vaccine comprising in combination non-replicating immunogen of porcine circo virus type 2 (PCV2), non-replicating immunogen of Mycoplasma hyopneumoniae and conjugated deoxynivalenol (DON) for protecting swine against an infection with porcine circo virus type 2, an infection with Mycoplasma hyopneumoniae and DON induced mycotoxicosis.

Abstract: The invention pertains to a combination of a first vaccine comprising anon-replicating immunogen of porcine circovirus type 2 (PCV-2) and a non-replicating immunogen of Mycoplasma hyopneumoniae, and a second vaccine comprising a live attenuated porcine reproductive and respiratory syndrome (PRRS) virus, for use in prophylactically treating a pig against an infection with PCV-2, an infection with Mycoplasma hyopneumoniae and an infection with PRRS virus, by associated separate injection of the first vaccine and the second vaccine into a tissue of the pig at a first and a second injection site respectively, wherein the first and second injection sites are at most 5 cm apart from each other.

Abstract: The present invention pertains to a vaccine comprising in combination non-replicating immunogen of porcine circo virus type 2 and live attenuated PRRS virus for use in prophylactically treating an animal against an infection with porcine circovirus type 2 (PCV2) and an infection with PRRS virus by administration of the vaccine into the dermis of the animal.

Abstract: A vaccine comprising nanoparticles in association with a Mycoplasma hyopneumoniae bacterin, wherein the nanoparticles comprise a cationic polysaccharide and an anionic phospholipid.

Abstract: The present invention pertains to a vaccine to protect a pig against an infection with Actinobacillus pleuropneumoniae, the vaccine comprising an RTX toxin of Actinobacillus pleuropneumoniae recombinantly expressed by a baculovirus, and a pharmaceutically acceptable carrier.

Abstract: The present invention pertains to a combination of a first vaccine comprising non-replicating immunogen of porcine circo virus type 2 (PCV2) and non-replicating immunogen of Mycoplasma hyopneumoniae, and a second vaccine comprising live attenuated porcine reproductive and respiratory syndrome (PRRS) virus, for use in prophylactically treating an animal against an infection with porcine circovirus type 2, an infection with Mycoplasma hyopneumoniae and an infection with PRRS virus, by associated non-mixed administration of the first vaccine and the second vaccine to the animal. The invention also pertains to a kit-of-parts comprising the first and second vaccine and to a method of protecting an animal against such infections using these vaccines.

Abstract: The present invention relates to a combination vaccine for swine, comprising non-replicating antigen from porcine circovirus type 2 (PCV2), and live porcine reproductive and respiratory syndrome virus (PRRSV); the combination vaccine is formulated as an oil-in-water emulsion, and is adjuvated with squalane and vitamin E-acetate. This combination vaccine was found to be immunologically effective against all pathogens: PCV2, and PRRSV.

Abstract: The present invention pertains to a vaccine to protect a pig against an infection with Actinobacillus pleuropneumoniae, the vaccine comprising an RTX toxin of Actinobacillus pleuropneumoniae recombinantly expressed by a baculovirus, and a pharmaceutically acceptable carrier.

Abstract: The present invention relates to a combination vaccine for swine, comprising non-replicating antigen from porcine circovirus type 2 (PCV2), and live porcine reproductive and respiratory syndrome virus (PRRSV); the combination vaccine is formulated as an oil-in-water emulsion, and is adjuvated with squalane and vitamin E-acetate. This combination vaccine was found to be immunologically effective against all pathogens: PCV2, and PRRSV.

Abstract: The present invention describes a process for the preparation of an antigen composition, which antigen composition can be used to prepare a ready-to-use vaccine for swine, for preventing or reducing infection by M. hyo or PCV2 and associated signs of disease. The process is characterised in that it comprises a step of admixing a PCV2 antigen to a pre-formed antigen/adjuvant complex of an M. hyo antigen adsorbed to an Aluminium-hydroxide adjuvant. This way a PCV2/M. hyo combination vaccine can be prepared that is highly effective already after a single administration, against infection and disease by M. hyo and PCV2 either when in single or in combined infections. Also the vaccine has very good safety upon administration, is ready-to-use, and is economically feasible.

Abstract: The present invention pertains to a combination of a first vaccine comprising non-replicating immunogen of porcine circo virus type 2 (PCV2) and non-replicating immunogen of Mycoplasma hyopneumoniae, and a second vaccine comprising live attenuated porcine reproductive and respiratory syndrome (PRRS) virus, for use in prophylactically treating an animal against an infection with porcine circovirus type 2, an infection with Mycoplasma hyopneumoniae and an infection with PRRS virus, by associated non-mixed administration of the first vaccine and the second vaccine to the animal. The invention also pertains to a kit-of-parts comprising the first and second vaccine and to a method of protecting an animal against such infections using these vaccines.

Abstract: The present invention pertains to a vaccine comprising in combination non-replicating immunogen of porcine circo virus type 2 and non-replicating immunogen of Mycoplasma hyopneumoniae and an adjuvant containing a nano-emulsion of mineral oil in water, for use in prophylactically treating an animal against an infection with porcine circovirus type 2 (PCV2) and an infection with Mycoplasma hyopneumoniae by administration of the vaccine into the dermis of the animal.

Abstract: The present invention pertains to a vaccine comprising in combination non-replicating immunogen of porcine circo virus type 2 and live attenuated PRRS virus for use in prophylactically treating an animal against an infection with porcine circovirus type 2 (PCV2) and an infection with PRRS virus by administration of the vaccine into the dermis of the animal.

Abstract: The present invention pertains to a vaccine comprising in combination killed whole cell Lawsonia intracellularis bacteria and porcine circo virus 2 (PCV2) ORF2 protein for use in protecting a pig against an infection with Lawsonia intracellularis and PCV2 by an intradermal administration of the vaccine. The invention also pertains to a method to protect a swine against an infection with Lawsonia intracellularis bacteria and PCV2.

Abstract: The present invention pertains to a vaccine comprising a non-replicating immunogen of porcine circo virus type 2 for use in prophylactically treating an animal that has circulating antibodies directed against porcine circo virus type 2, against an infection with pathogenic porcine circo virus type 2 by a single dose administration of the vaccine into the dermis of the animal.

Abstract: The present invention describes a process for the preparation of an antigen composition, which antigen composition can be used to prepare a ready-to-use vaccine for swine, for preventing or reducing infection by M. hyo or PCV2 and associated signs of disease. The process is characterised in that it comprises a step of admixing a PCV2 antigen to a pre-formed antigen/adjuvant complex of an M. hyo antigen adsorbed to an Aluminium-hydroxide adjuvant. This way a PCV2/M. hyo combination vaccine can be prepared that is highly effective already after a single administration, against infection and disease by M. hyo and PCV2 either when in single or in combined infections. Also the vaccine has very good safety upon administration, is ready-to-use, and is economically feasible.